Ischemic Heart Disease | Pharmacology Mentor

1. Definition & Epidemiology

Ischemic heart disease (IHD)—also called coronary artery disease (CAD)—is defined by impaired blood supply (ischemia) to the myocardium, usually due to narrowing or obstruction of the coronary arteries by atherosclerotic plaque. IHD is the leading cause of morbidity and mortality worldwide, particularly affecting adults over age 40 and those with major cardiovascular risk factors.

2. Pathophysiology

Key Mechanism: Atherosclerosis—accumulation of cholesterol-laden plaques within coronary arteries causes luminal narrowing, reducing oxygen delivery to heart muscle.
Acute events: Rupture of an unstable plaque with subsequent thrombus formation may cause complete occlusion, resulting in acute myocardial infarction (MI).
Risk Factors:
- Non-modifiable: Age, male sex, family history/genetics.
- Modifiable: Hypertension, dyslipidemia, diabetes, obesity, smoking, sedentary lifestyle, stress, unhealthy diet.

#cardiac ischemia anatomical illustration drawn in cartoon style

3. Clinical Presentation

Stage	Symptoms	Notes
Chronic stable	Exertional chest pain (angina), fatigue, shortness of breath	Symptoms relieved by rest/nitroglycerin
Acute coronary syndrome	Persistent chest pain, diaphoresis, nausea, palpitations	May signal MI; emergency
Silent ischemia	No typical angina; atypical symptoms (esp. elderly, diabetic patients)	Detected via ECG or imaging
Heart failure	Edema, orthopnea, dyspnea	Due to chronic ischemia

4. Diagnostic Approach

Test	Principle	Diagnostic Value
ECG	Records cardiac electrical activity	Detects ischemia, arrhythmia
Stress test	Monitors heart under exertion	Provokes symptoms, unmasking ischemia
Echocardiogram	Ultrasound imaging of heart	Assess function, motion, ejection fraction
Coronary angiogram	Dye and X-ray visualizes arteries	Gold standard for obstruction
CT/MRI coronary imaging	Noninvasive, advanced assessment	Useful for non-acute evaluation
Blood tests	Troponin, CK-MB, lipid/liver/kidney profiles	Confirm MI, metabolic risk

5. Management Strategies

A. Lifestyle Modification

Mediterranean/heart-healthy diet (limit saturated fat, cholesterol, sugar).
Regular aerobic exercise (30–45 min most days).
Smoking cessation.
Weight management and stress reduction.
Blood pressure and diabetes control.

B. Pharmacologic Therapy

Drug Class	Examples	Purpose/Mechanism
Antiplatelets	Aspirin, clopidogrel	Prevent clot formation
Statins	Atorvastatin, rosuvastatin	Lower LDL, stabilize plaques
Beta-blockers	Metoprolol, atenolol	Reduce heart rate, oxygen demand
ACE inhibitors/ARBs	Enalapril, losartan	Lower blood pressure, prevent remodeling
Nitrates	Nitroglycerin	Relieve angina (vasodilation)
Calcium channel blockers	Diltiazem, amlodipine	Vasodilation, symptom relief
Newer agents	PCSK9 inhibitors, SGLT2 inhibitors (in comorbid diabetes, HF)	Reduce risk, target specific populations

Medication Adherence: Lifelong commitment; regular review for interactions and side effects.

C. Revascularization

Procedure	Indication	Highlights
Percutaneous Coronary Intervention (PCI)	Acute MI, lifestyle-resistant angina	Balloon angioplasty ± stent placement
Coronary Artery Bypass Grafting (CABG)	Left main/multivessel, DM, failed PCI	Surgical rerouting using graft

6. Follow-Up and Long-Term Care

Regular assessment: Blood pressure, lipid profile, glycemic status, ECGs.
Comorbidity management: Diabetes, kidney disease, arrhythmia.
Patient education: Symptom recognition, emergency response, medication side effects.
Cardiac rehabilitation: Supervised exercise, risk factor education, psychological support.

7. Prognosis and Prevention

Prognosis depends on degree of vessel involvement, comorbidity control, adherence to therapy.
Primary prevention: Risk factor control before onset.
Secondary prevention: Aggressive intervention post-MI or diagnosis to prevent recurrence or progression.

Summary Table: Textbook Comparison of Key IHD Treatments

Strategy	Primary Effect	Most Effective For	Key Textbook References
Lifestyle	Reduces overall CV risk	All patients, prevention	Braunwald, Harrison’s
Antiplatelets	Prevents acute MI	All diagnosed IHD	Katzung, G&G, NICE/ACC/AHA
Statins	Lower cholesterol, resolve plaques	Dyslipidemia, secondary prevention	G&G, ESC Guidelines
PCI	Immediate reperfusion	Acute STEMI/NSTEMI	ACC/AHA
CABG	Complete anatomical correction	Complex/multivessel disease	Harrison’s, ACC/AHA

References

Braunwald’s Heart Disease (11th Edition)
Harrison’s Principles of Internal Medicine (21st Edition)
Goodman & Gilman’s The Pharmacological Basis of Therapeutics (13th Edition, Cardiac Drugs section)
Katzung BG, Basic & Clinical Pharmacology (15th Edition)
ACC/AHA/ESC Guidelines on management of coronary artery disease

With a patient-focused, scientifically accurate approach, this chapter brings together etiology, symptomatology, diagnostic workup, therapy, and prevention as recommended by top clinical textbooks and guidelines.

How to cite this page - Vancouver Style

anonymous, . Ischemic Heart Disease: Causes, signs and treatment options. Pharmacology Mentor. Available from: https://pharmacologymentor.com/ischemic-heart-disease-causes-signs-and-treatment-options/. Accessed on March 1, 2026 at 22:47.

Post Views: 61

Quiz on IHD

✓ Passing Score: 50%

📝 Questions: 22

🎓 Practice Quiz

Welcome! This is a practice quiz to test your knowledge.

Please enter your details below to participate. Your results will be emailed to you upon completion.

Your Information

Name *

Email *

Question 1 of 22

A 68-year-old male with stable angina is on optimal medical therapy, including a beta-blocker, aspirin, and a high-intensity statin. He continues to have exertional angina that limits his daily activities. His physician is considering adding a third antianginal agent. Which of the following medications is a direct vasodilator that can be used to improve anginal symptoms by reducing myocardial oxygen demand through peripheral vasodilation? *

Ranolazine Amlodipine Ivabradine Trimetazidine Isosorbide mononitrate

A 70-year-old female with a history of myocardial infarction 2 years ago presents with symptoms of heart failure. She is already on an ACE inhibitor, a beta-blocker, and a loop diuretic. Her ejection fraction is 30%. Her potassium is 4.8 mEq/L. Which of the following medications would be the most appropriate addition to her regimen to improve her prognosis? *

Hydralazine/isosorbide dinitrate Sacubitril/valsartan Ivabradine Digoxin Spironolactone

A 58-year-old female with a history of CAD presents with exertional chest pain. She is started on a high-intensity statin and aspirin. Her LDL cholesterol remains elevated at 120 mg/dL. Which of the following medications is the most appropriate addition to further lower her LDL cholesterol? *

Omega-3 fatty acids Fenofibrate Niacin Ezetimibe Gemfibrozil

A 70-year-old male with CAD and chronic kidney disease (CKD) stage 4 is admitted with unstable angina. He is to be treated with PCI. He is on aspirin. Which of the following P2Y12 inhibitors requires dose adjustment or is contraindicated in significant renal impairment? *

Ticagrelor Cangrelor Clopidogrel Prasugrel Ticlopidine

A 68-year-old female presents with acute onset of dyspnea and chest pain that started 2 hours ago. Her ECG shows ST-segment depression in the anterior leads. Cardiac enzymes reveal elevated troponin I. She is diagnosed with a non-ST-elevation myocardial infarction (NSTEMI). Which of the following is the most appropriate initial management strategy? *

Observe for 24 hours and repeat cardiac enzymes Start aspirin and a P2Y12 inhibitor, and consider anticoagulation Immediate coronary angiography and revascularization Initiate beta-blocker therapy and aspirin only Administer intravenous thrombolytics

A 65-year-old male with diabetes and hyperlipidemia is experiencing exertional angina. He is on a moderate-intensity statin and aspirin. His physician wants to add a medication to further reduce his risk of cardiovascular events. Which of the following medications, when added to statin and aspirin, has been shown to reduce cardiovascular events in patients with stable ischemic heart disease and a history of myocardial infarction or other atherosclerotic disease? *

Fenofibrate Ezetimibe Niacin Ramipril Omega-3 fatty acids (prescription strength)

A 60-year-old male with a history of hypertension and hyperlipidemia is experiencing stable angina. His physician is considering starting a statin. Which of the following statins would be considered a high-intensity statin, indicated for primary prevention of atherosclerotic cardiovascular disease in patients with established CAD or multiple risk factors? *

Atorvastatin 80 mg daily Simvastatin 10 mg daily Lovastatin 40 mg daily Pravastatin 20 mg daily Rosuvastatin 5 mg daily

A 58-year-old female with a history of hypertension and hyperlipidemia presents with exertional chest pain that resolves with rest. She denies any pain at rest. Her ECG is normal at rest. She is scheduled for a stress test. Which of the following diagnostic modalities is most appropriate to assess for significant coronary artery stenosis in this patient? *

Cardiac MRI Echocardiogram Holter monitor Myocardial perfusion imaging (MPI) with stress Coronary angiography

A 65-year-old male with a history of MI is on optimal medical therapy including a beta-blocker, ACE inhibitor, and statin. He continues to experience angina despite these medications. Which of the following medications is considered a second-line agent for symptom relief in stable angina? *

Ivabradine Verapamil Amlodipine All of the above Ranolazine

A 50-year-old male with a history of hypertension presents with sudden, severe, tearing chest pain radiating to his back. His blood pressure is 190/110 mmHg, and his pulse is 110 bpm. An aortic dissection is suspected. Which of the following medications is **contraindicated** in the initial management of suspected aortic dissection? *

Opioid analgesics (e.g., morphine) Angiotensin-converting enzyme (ACE) inhibitors (e.g., enalapril) Vasodilators (e.g., nitroprusside) Beta-blockers (e.g., labetalol) Calcium channel blockers (e.g., verapamil)

A 45-year-old male with no significant past medical history presents with sudden onset of severe, substernal chest pain radiating to his jaw, accompanied by nausea and diaphoresis. His ECG shows diffuse ST-segment elevation. He is diagnosed with a massive anterior STEMI. He is allergic to aspirin. Which of the following is the most appropriate initial antiplatelet therapy in this scenario? *

Clopidogrel 75 mg PO daily Ticagrelor 180 mg PO loading dose Prasugrel 60 mg PO loading dose No antiplatelet therapy due to allergy Abciximab intravenously

A 60-year-old male with a history of CAD is admitted with an NSTEMI. He is started on aspirin and ticagrelor, and anticoagulation with heparin. He develops a rash and pruritus after 2 days of ticagrelor. His troponin levels are still rising. Which of the following is the most appropriate management for his ticagrelor-induced rash? *

Discontinue ticagrelor and consider a glycoprotein IIb/IIIa inhibitor Discontinue ticagrelor and restart aspirin monotherapy Discontinue ticagrelor and switch to clopidogrel Continue ticagrelor and add an antihistamine Discontinue ticagrelor and switch to prasugrel

A 65-year-old male presents to the emergency department with sudden onset of crushing chest pain radiating to his left arm, accompanied by diaphoresis and nausea. His vital signs are: BP 150/90 mmHg, HR 95 bpm, RR 20/min, SpO2 98% on room air. An ECG shows ST-segment elevation in leads II, III, and aVF. Which of the following is the most appropriate initial pharmacologic management for this patient? *

Intravenous nitroglycerin infusion Oral metoprolol 25 mg PO every 6 hours Aspirin 81 mg PO daily Clopidogrel 75 mg PO daily Sublingual nitroglycerin tablet

A 75-year-old male with a history of ischemic heart disease develops acute shortness of breath and chest pain. He is diagnosed with acute decompensated heart failure and a concurrent myocardial infarction. He is hemodynamically unstable with hypotension. Which of the following medications should be used with extreme caution or avoided in this patient due to its negative inotropic effects and potential to worsen hypotension? *

Beta-blockers ACE inhibitors Furosemide Aspirin Nitroglycerin

A 55-year-old male with stable angina is initiated on a beta-blocker for symptom control. He has a history of asthma. Which of the following beta-blockers would be the most appropriate choice, considering his respiratory history? *

Metoprolol Propranolol Nebivolol Atenolol Bisoprolol

A 70-year-old male with ischemic heart disease presents with chest pain and is found to have an inferior STEMI. He undergoes successful primary PCI with placement of a drug-eluting stent. He is discharged on dual antiplatelet therapy (aspirin and ticagrelor) for 12 months. He also has a history of gout and is taking allopurinol. Which of the following is a potential drug interaction to monitor for? *

Allopurinol inhibits the metabolism of ticagrelor, increasing its levels Allopurinol can increase the risk of stent thrombosis Ticagrelor can cause bone marrow suppression, similar to allopurinol Increased risk of bleeding with ticagrelor and allopurinol Ticagrelor can increase uric acid levels, exacerbating gout

A 62-year-old male presents with new-onset shortness of breath and fatigue. He has a history of CAD and a previous myocardial infarction 5 years ago. His ejection fraction is 35%. He is currently on lisinopril, metoprolol, and furosemide. His vital signs are stable. Which of the following medications is most likely to improve his long-term prognosis and reduce hospitalizations for heart failure? *

Carvedilol Spironolactone Sacubitril/valsartan Hydralazine Digoxin

A 55-year-old male presents with acute chest pain suggestive of an MI. His ECG shows ST-segment elevation in leads V1-V4. He is rushed to the cardiac catheterization lab for primary percutaneous coronary intervention (PCI). He is to receive dual antiplatelet therapy (DAPT). Which of the following P2Y12 inhibitors is generally preferred in the setting of primary PCI for STEMI? *

Ticlopidine Cangrelor Prasugrel Ticagrelor Clopidogrel

A 75-year-old female with known ischemic heart disease develops acute chest pain at rest. Her ECG shows ST-segment depression in the anterior leads, and her troponin levels are elevated. She is diagnosed with an NSTEMI. Her blood pressure is 110/70 mmHg, and her heart rate is 70 bpm. She is allergic to penicillin. Which of the following medications should be avoided due to a potential cross-reactivity or contraindication? *

Clopidogrel Heparin Aspirin Nitroglycerin Metoprolol

A 70-year-old male with known coronary artery disease (CAD) is admitted with an acute myocardial infarction. He is treated with percutaneous coronary intervention (PCI) and receives a drug-eluting stent. He is prescribed dual antiplatelet therapy (DAPT) with aspirin and ticagrelor. He also has a history of peptic ulcer disease. Which of the following is the most significant drug interaction to consider for this patient? *

Ticagrelor and statins Aspirin and NSAIDs Aspirin and clopidogrel Aspirin and warfarin Ticagrelor and CYP3A4 inhibitors

A 62-year-old male with a history of CAD and an ejection fraction of 40% presents with new-onset atrial fibrillation. He is experiencing symptoms of angina. He is currently on aspirin and metoprolol. Which of the following medications is **contraindicated** in this patient for rate control of his atrial fibrillation due to its potential to worsen myocardial ischemia? *

Amiodarone Diltiazem Metoprolol Verapamil Digoxin

A 72-year-old male with a history of CAD and atrial fibrillation is on warfarin for stroke prevention. He presents with worsening exertional chest pain. He is prescribed sublingual nitroglycerin, which provides temporary relief. His physician is considering adding a medication to improve his exertional capacity. Which of the following medications would be most appropriate, considering his anticoagulation status and history? *

Diltiazem Amlodipine Verapamil Ivabradine Ranolazine

Medical Disclaimer

The medical information on this post is for general educational purposes only and is provided by Pharmacology Mentor. While we strive to keep content current and accurate, Pharmacology Mentor makes no representations or warranties, express or implied, regarding the completeness, accuracy, reliability, suitability, or availability of the post, the website, or any information, products, services, or related graphics for any purpose. This content is not a substitute for professional medical advice, diagnosis, or treatment; always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition and never disregard or delay seeking professional advice because of something you have read here. Reliance on any information provided is solely at your own risk.